Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases

MT Newswires Live07-08

Niagen Bioscience (NAGE) said Wednesday that its NAD Pharmaceuticals unit will undertake a pharmaceutical program to develop therapies for accelerated aging and rare genetic diseases.

The program will primarily focus on how NAD+, a coenzyme vital for energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which DNA misrepair and mitochondrial dysfunction are foundational underlying causes, the company said.

Niagen said that NB4168, a derivative of the NAD+ precursor nicotinamide riboside, is the first investigational pharmaceutical product candidate within the program, with Ataxia Telangiectasia as the initial indication.

Shares of the company were up 1.5% in Wednesday's premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649348999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649348999","market":"us","top_or_hot":-1,"title":"Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> (NAGE) said Wednesday that its NAD Pharmaceuticals unit will undertake a pharmaceutical program to develop therapies for accelerated aging and rare genetic diseases.</p><p>The program will primarily focus on how NAD+, a coenzyme vital for energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which DNA misrepair and mitochondrial dysfunction are foundational underlying causes, the company said.</p><p>Niagen said that NB4168, a derivative of the NAD+ precursor nicotinamide riboside, is the first investigational pharmaceutical product candidate within the program, with Ataxia Telangiectasia as the initial indication.</p><p>Shares of the company were up 1.5% in Wednesday's premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNiagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-08 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> (NAGE) said Wednesday that its NAD Pharmaceuticals unit will undertake a pharmaceutical program to develop therapies for accelerated aging and rare genetic diseases.</p><p>The program will primarily focus on how NAD+, a coenzyme vital for energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which DNA misrepair and mitochondrial dysfunction are foundational underlying causes, the company said.</p><p>Niagen said that NB4168, a derivative of the NAD+ precursor nicotinamide riboside, is the first investigational pharmaceutical product candidate within the program, with Ataxia Telangiectasia as the initial indication.</p><p>Shares of the company were up 1.5% in Wednesday's premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NAGE","symbol_name":"Niagen Bioscience","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649348999","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649348999","pubTimestamp":1783516678,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Niagen Bioscience  said Wednesday that its NAD Pharmaceuticals unit will undertake a pharmaceutical program to develop therapies for accelerated aging and rare genetic diseases.The program will primarily focus on how NAD+, a coenzyme vital for energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which DNA misrepair and mitochondrial dysfunction are foundational underlying causes, the company said.Niagen said that NB4168, a derivative of the NAD+ precursor nicotinamide riboside, is the first investigational pharmaceutical product candidate within the program, with Ataxia Telangiectasia as the initial indication.Shares of the company were up 1.5% in Wednesday's premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NAGE":"Niagen Bioscience","BK4121":"生命科学工具和服务","BK4183":"个人用品"},"translate_title":"Niagen Bioscience启动加速衰老和罕见遗传疾病疗法开发计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAGE":1.5},"content_text":"Niagen Bioscience (NAGE) said Wednesday that its NAD Pharmaceuticals unit will undertake a pharmaceutical program to develop therapies for accelerated aging and rare genetic diseases.The program will primarily focus on how NAD+, a coenzyme vital for energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which DNA misrepair and mitochondrial dysfunction are foundational underlying causes, the company said.Niagen said that NB4168, a derivative of the NAD+ precursor nicotinamide riboside, is the first investigational pharmaceutical product candidate within the program, with Ataxia Telangiectasia as the initial indication.Shares of the company were up 1.5% in Wednesday's premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649348999","isCrawlerRequest":true}